Biogen Acquires HI-Bio for $1.15 Billion to Enhance Immunology Pipeline

The acquisition includes potential milestone payments of up to $650 million, focusing on treatments for rare kidney diseases.

Biogen's purchase of HI-Bio aims to strengthen its portfolio of immunology medicines.
HI-Bio's lead drug, felzartamab, targets severe immune-mediated kidney diseases.
The deal includes $1.15 billion upfront and up to $650 million in milestone payments.
Biogen's acquisition strategy follows declining sales in its multiple sclerosis drug line.
Felzartamab has shown promise in Phase 2 trials and will advance to Phase 3.